CohBar to Present at Upcoming Investor Conferences

Rhea-AI Summary

CohBar, a clinical stage biotechnology company (NASDAQ: CWBR), announced that CEO Dr. Joseph Sarret will present at two upcoming investor conferences in September 2021. The presentations will be at the H.C. Wainwright Annual Global Investment Conference from September 13-15, and the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30 at 2:00 PM ET. Webcasts will be available for on-demand access. CohBar focuses on developing mitochondria-based therapeutics for chronic diseases and has made significant strides in clinical trials, including its lead compound CB4211 for nonalcoholic steatohepatitis (NASH).

MENLO PARK, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the following investor conferences in September.

H.C. Wainwright Annual Global Investment Conference
September 13 – 15, 2021
Webcast: The presentation may be accessed via webcast on demand using the following link: https://journey.ct.events/view/ca7b4b79-1e8b-4452-b5d2-db8298a7f923

Cantor Fitzgerald Virtual Global Healthcare Conference
Thursday, September 30, 2021 at 2:00pm ET
Webcast: The presentation may be accessed via webcast at the scheduled time, or following the presentation, using the following link: https://wsw.com/webcast/cantor12/cwbr/2083340

A replay of the webcasts will be available in the events section of the CohBar website for two weeks following the presentation.

About CohBar

CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring mitochondrial-derived peptides within the mitochondrial genome that regulate metabolism and cell death, and whose biological activity declines with age. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar’s efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases, cancer, acute respiratory distress syndrome (ARDS), type 2 diabetes, and cardiovascular and neurodegenerative diseases. The company’s lead compound, CB4211, which is under development for the treatment of NASH and obesity, recently completed a successful Phase 1a/1b clinical trial. In addition, CohBar has four preclinical programs, the most advanced of which is CB5138-3, a peptide with broad anti-fibrotic and anti-inflammatory properties. This program is currently in IND-enabling studies with the goal of filing an IND and initiating a First-in-Human study in 2022 with an initial indication of idiopathic pulmonary fibrosis. The company also has a program in ARDS, including COVID-19 associated ARDS, as well as two peptide families with potential utility in treating various forms of cancer.

Forward-Looking Statements

This news release contains forward-looking statements that are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “should,” “would,” “project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely” or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to statements regarding timing and anticipated outcomes of research and clinical trials for our mitochondria based therapeutic (MBT) candidates; expectations regarding the growth of MBTs as a significant future class of drug products; and statements regarding anticipated therapeutic properties and potential of our mitochondrial peptide analogs, MBTs and other potential therapies. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: our ability to successfully advance drug discovery and development programs, including the delay or termination of ongoing clinical trials and the timing of announcements and updates relating to our clinical trials and related data; our possible inability to mitigate the prevalence and/or persistence of the injection site reactions, receipt of unfavorable feedback from regulators regarding the safety or tolerability of CB4211 or the possibility of other developments affecting the viability of CB4211 or CB5138-3 as a clinical candidate or its commercial potential; results that are different from earlier data results including less favorable results that may not support further clinical development; our ability to raise additional capital when necessary to continue our operations; our ability to recruit and retain key management and scientific personnel; the risk that our intellectual property may not be adequately protected; our ability to establish and maintain partnerships with corporate and industry partners; and risks related to the impact on our business of the COVID-19 pandemic or similar public health crises. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com. 

You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.

Contacts:
Jordyn Tarazi
Director of Investor Relations
CohBar, Inc.
(650) 445-4441
Jordyn.tarazi@cohbar.com

Media:
Nancy Thompson
Vorticom, Inc.
(212)532-2208
Nancyt@vorticom.com

FAQ

What are the key events for CohBar in September 2021?

CohBar will present at the H.C. Wainwright Annual Global Investment Conference from September 13-15 and at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021.

Where can I access the webcasts for CohBar's investor presentations?

The webcasts for CohBar's presentations can be accessed on their official website following each event.

What is the focus of CohBar's research and development?

CohBar focuses on mitochondria-based therapeutics aimed at treating chronic and age-related diseases.

What is the current status of CohBar's lead compound CB4211?

CohBar's lead compound CB4211 is currently under development for the treatment of NASH and obesity and has completed a successful Phase 1a/1b clinical trial.

What types of diseases is CohBar targeting with its therapeutics?

CohBar's therapeutics target a range of diseases, including NASH, obesity, fibrotic diseases, cancer, ARDS, type 2 diabetes, and neurodegenerative diseases.